Peptide Clinic
London
Peptide Therapy
Diagnostics-First.

It is a doctor-led private medical advisory consultation focused on the current scientific literature surrounding research peptide compounds, interpreted in the context of your individual biomarker data. Peptides are short chains of amino acids that function as signaling molecules. Most compounds discussed are subjects of ongoing research and are not licensed medicines.

Consultations begin with mandatory bloodwork and are personally overseen by Dr. Ethan Hausman-Marquis. No program is discussed without your data.

No. The compounds referenced are research compounds. They are not licensed medicines under the Human Medicines Regulations 2012 for any therapeutic, wellness, longevity, or aesthetic use discussed at The Catalyst Clinic. A small number hold licences elsewhere for narrow, specific indications; those licences do not extend to this context.

Discussions occur within a regulated private advisory consultation. Where clinically appropriate, a GMC-registered doctor may exercise prescribing discretion; any compounds are dispensed independently by GMP-certified compounding pharmacies, not by the clinic itself. No efficacy claims are made.

It depends on the specific compound and how it is handled. Most research peptides are not licensed medicines. Supplying unlicensed medicinal products is restricted under the Human Medicines Regulations 2012, and medicinal claims for unlicensed products cannot be advertised to the public (ASA/MHRA rules).

The Catalyst Clinic operates as a private medical advisory clinic with consultations by registered doctors. It does not sell or dispense compounds. Patients should understand the regulatory status. Competitive athletes must check the current WADA prohibited list.

Responsible advisory work requires individual data. Without a clear picture of your biomarkers, medical history, and relevant factors, no appropriate personalized discussion can take place.

Every consultation begins with comprehensive bloodwork (60+ biomarkers in London, included in the fee). DEXA body composition scanning is also included in London. Results are reviewed personally by the consulting doctor. This diagnostics-first approach is a core clinical standard.

Safety evidence varies widely between compounds. A few have more human data in specific licensed contexts; many have limited or mainly preclinical evidence. Some compounds have had clinical development stopped over safety signals. This is why bloodwork precedes any discussion and monitoring continues throughout a program.

Mild effects reported in the literature can include injection-site reactions, temporary water retention or appetite changes, or headaches. Serious adverse effects are possible, especially with poor-quality products, improper use, or in people with contraindications. The clinic screens for contraindications and interactions. Advisory consultations are not suitable for everyone. No safety or efficacy guarantees are made.

It is a doctor-led advisory clinic with mandatory comprehensive bloodwork and personal physician review of every result before any program is discussed. Protocols are fully personalized (no templates). Optional genetic/genomic testing with counseling is available. Ongoing monthly doctor reviews and repeat bloodwork every 4–5 months are standard.

Compounds (when accessed) come exclusively from GMP-certified, EMA-regulated or FDA-registered compounding pharmacies with certificates of analysis. The approach emphasizes scientific rigor, transparency about research status, and regulatory alignment rather than product sales. Dr. Ethan Hausman-Marquis (PhD in Cell and Genomic Biology, nearly 20 years of peptide research, three published books) personally oversees consultations.

He is the founder and lead physician. He holds a PhD in Cell and Genomic Biology, has nearly two decades of specialist peptide research experience, is US board-certified in regenerative medicine and European board-certified in longevity medicine, and is a member of the International Peptide Society and A4M.

He has published three books on peptides and hosts the podcast The Science of Ageless Living. He personally reviews diagnostics and oversees advisory programs at the London clinic and remotely.

Programs start from £600 per month. The initial consultation is £200. In London, bloodwork and DEXA scanning are included in the monthly fee. For remote patients, diagnostics are additional and arranged via partner labs. Optional genetic testing is priced separately.

Typical inclusions are a data-driven advisory protocol, personal diagnostic review, monthly reviews, and full written documentation. Exact costs depend on the individualized program. No outcomes are guaranteed.

It starts with mandatory diagnostics. The consulting physician reviews the results personally and discusses relevant areas of peptide research in the context of your data, history, medications, and goals. A documented personalized advisory protocol is developed if appropriate.

This is followed by induction, monthly reviews, and periodic repeat bloodwork. Full transparency about research status and the regulatory framework is provided, along with informed consent covering the advisory nature of the service.